icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
the actual benefit of HEMANGIOL 3.75 mg/ml oral solution is substantial in the indication in the Marketing Authorisation.
Clinical Added Value
moderate
HEMANGIOL 3.75 mg/ml oral solution provides a moderate improvement in actual benefit (IAB III) in the treatment of proliferating infantile haemangioma requiring systemic therapy.
eNq9mF1v2jAUhu/5FVHuiYGWlk6BamPthrRqjBZt2g1ykpPizLVTfwDdr59D6EYnR11NvcvEzntOfF4/PnJ8vrmjwQqEJJwNw27UCQNgKc8Iux2G85vL9iA8H7XiAq/w3jQzL+r1wiClWMphWI1GCWAmo29Xn96D+R5EOGoFMU8KSNWTeVoRGn3EcnmFy2pOEK84yYI7UEueDcNSq+3bIJZKmCxGay5+yBKnEKPdm/3RYnG8/z5Gldg/qGoJ4hNmt1ZRYE6aqRYCmBpjBbdcPDTke+SkTeQMJNcihSlWy6ngK5JBZg2RYyrBKUi+zq5BrCioKohVHBXpnXQSxwXezOB+Yk/6rRkdq41qd9rd0+7x4LTT73dOBj2nUGJvqexVMD+B0kX3tH90dtxHwFAhESUJSjhXZg4u24wrkj9EhXQs15QLhamnQhE5fuo1T3EE3D9riIzIkuJqpUrXpcICm2EQhgj+fqT6gxthGEXNmv2lzzSl6IVZz3cE8ZRxBagx10w1gORy5roQY84UbJor6sY+tdl5kYB8PdmfnNm5P9UJJakr5QyHNEg1n02aIeeZD++whLnwB4ivhGV8LV8fPPuF9pR9uWWnVbQUWXfROxucdPt953313biq4Ry60IKXgAySiDyENBOW80MZY4xql3q0qU+HbhsknmIKDS3SwpFAxpqPHZ038/vbWPWAVfTDxY2rY75oEA/X20erNMmGv2vthmcfzDf+bEz85W6vN72X5lkLO0yWSpXyDULr9TpaYtmW2KxSlIv/wf+9U9hfN+/lqK9bn5qhnlJP6sPxZUVz3XzPNQOHNri773eNtDWGEhoOqEXNaW80nVy8PqD/dLfe0p4+AYq/MNtOFCvCma92SCdWxcOOBFNXdikMID7nOWm4XWn0ZYzqm51RK0bVrc6o9Qt90wHY
mEtvVwz4HJe6pTJt